You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGrepafloxacin
Accession NumberDB00365  (APRD01003)
TypeSmall Molecule
GroupsWithdrawn
DescriptionGrepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Grepafloxacin was withdrawn in the United States due to its side effect of lengthening the QT interval on the electrocardiogram, leading to cardiac events and sudden death. [Wikipedia]
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RaxarTablet200 mgOralOtsuka Pharma Gmbh1998-07-011999-10-27Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Grepafloxacin hydrochloride
ThumbNot applicableDBSALT000913
Categories
UNIIL1M1U2HC31
CAS number119914-60-2
WeightAverage: 359.3947
Monoisotopic: 359.16451979
Chemical FormulaC19H22FN3O3
InChI KeyAIJTTZAVMXIJGM-UHFFFAOYSA-N
InChI
InChI=1S/C19H22FN3O3/c1-10-8-22(6-5-21-10)15-7-14-16(11(2)17(15)20)18(24)13(19(25)26)9-23(14)12-3-4-12/h7,9-10,12,21H,3-6,8H2,1-2H3,(H,25,26)
IUPAC Name
1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O
Pharmacology
IndicationFor treatment of adults with mild to moderate infections caused by susceptible strains of Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis.
Structured Indications Not Available
PharmacodynamicsGrepafloxacin has in vitro activity against a wide range of gram-positive and gram-negative aerobic microorganisms, as well as some atypical microorganisms.
Mechanism of actionGrepafloxacin exerts its antibacterial activity by inhibiting bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, essential enzymes for duplication, transcription, and repair of bacterial DNA.
TargetKindPharmacological actionActionsOrganismUniProt ID
DNA gyrase subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43700 details
DNA topoisomerase 4 subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43702 details
Related Articles
AbsorptionRapidly and extensively absorbed following oral administration. The absolute bioavailability is approximately 70%.
Volume of distributionNot Available
Protein binding50%
Metabolism

Primarily hepatic via CYP1A2 and CYP3A4. The major metabolite is a glucuronide conjugate; minor metabolites include sulfate conjugates and oxidative metabolites. The oxidative metabolites are formed mainly by the cytochrome P450 enzyme CYP1A2, while the cytochrome P450 enzyme CYP3A4 plays a minor role. The nonconjugated metabolites have little antimicrobial activity compared with the parent drug, and the conjugated metabolites have no antimicrobial activity

Route of eliminationNot Available
Half life15 ± 3 hours
ClearanceNot Available
ToxicityWithdrawn from the US market in 1999 due to associations with QTc prolongation and adverse cardiovascular events.
Affected organisms
  • Enteric bacteria and other eubacteria
  • Streptococcus pneumoniae
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Grepafloxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Grepafloxacin.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Grepafloxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Grepafloxacin.Experimental, Illicit
AbirateroneThe serum concentration of Grepafloxacin can be increased when it is combined with Abiraterone.Approved
AcarboseGrepafloxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Grepafloxacin.Approved
AceclofenacAceclofenac may increase the neuroexcitatory activities of Grepafloxacin.Approved
AcenocoumarolGrepafloxacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Grepafloxacin can be increased when it is combined with Acetaminophen.Approved
AcetovanilloneAcetovanillone may increase the neuroexcitatory activities of Grepafloxacin.Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Grepafloxacin.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Grepafloxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Grepafloxacin.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Grepafloxacin.Approved
AlbendazoleThe serum concentration of Grepafloxacin can be increased when it is combined with Albendazole.Approved, Vet Approved
AlbiglutideGrepafloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Grepafloxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Grepafloxacin.Experimental
AlectinibThe serum concentration of Grepafloxacin can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Grepafloxacin can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Grepafloxacin.Approved, Investigational
AlogliptinGrepafloxacin may increase the hypoglycemic activities of Alogliptin.Approved
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineThe serum concentration of Grepafloxacin can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Grepafloxacin.Approved, Investigational
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Grepafloxacin.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Grepafloxacin.Approved
Aminohippuric acidThe serum concentration of Grepafloxacin can be increased when it is combined with Aminohippuric acid.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Grepafloxacin.Approved
AmiodaroneThe metabolism of Grepafloxacin can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Grepafloxacin can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Grepafloxacin can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Grepafloxacin can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Grepafloxacin can be increased when it is combined with Amsacrine.Approved
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Grepafloxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Grepafloxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Grepafloxacin.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Grepafloxacin.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Grepafloxacin.Approved
ApremilastApremilast may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational
AprepitantThe serum concentration of Grepafloxacin can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Grepafloxacin.Approved, Investigational
AstemizoleThe serum concentration of Grepafloxacin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Grepafloxacin can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Grepafloxacin can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Grepafloxacin can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Grepafloxacin can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Grepafloxacin.Approved, Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Grepafloxacin.Approved
AzithromycinThe serum concentration of Grepafloxacin can be increased when it is combined with Azithromycin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Grepafloxacin.Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Grepafloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Grepafloxacin.Approved, Investigational
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
BenzocaineThe serum concentration of Grepafloxacin can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Grepafloxacin can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Grepafloxacin.Approved, Vet Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Grepafloxacin.Approved, Vet Approved
Betulinic AcidBetulinic Acid may increase the neuroexcitatory activities of Grepafloxacin.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Grepafloxacin.Approved, Investigational
BexaroteneThe serum concentration of Grepafloxacin can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Grepafloxacin can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BoceprevirThe metabolism of Grepafloxacin can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Grepafloxacin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Grepafloxacin can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Grepafloxacin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Grepafloxacin.Approved
BromfenacBromfenac may increase the neuroexcitatory activities of Grepafloxacin.Approved
BromocriptineThe serum concentration of Grepafloxacin can be increased when it is combined with Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Grepafloxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Grepafloxacin.Approved
BuprenorphineThe serum concentration of Grepafloxacin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Grepafloxacin can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Grepafloxacin.Approved
CaffeineThe serum concentration of Grepafloxacin can be increased when it is combined with Caffeine.Approved
CalciumCalcium can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Nutraceutical
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium citrateCalcium citrate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Grepafloxacin.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Grepafloxacin.Approved
CandesartanThe serum concentration of Grepafloxacin can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Grepafloxacin can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Grepafloxacin can be increased when combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Grepafloxacin.Approved
CarprofenCarprofen may increase the neuroexcitatory activities of Grepafloxacin.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Grepafloxacin can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Grepafloxacin can be increased when it is combined with Caspofungin.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Grepafloxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational
CeritinibThe serum concentration of Grepafloxacin can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Grepafloxacin.Withdrawn
ChloroquineChloroquine may increase the neuroexcitatory activities of Grepafloxacin.Approved, Vet Approved
ChlorpromazineThe serum concentration of Grepafloxacin can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Grepafloxacin can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Grepafloxacin can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Grepafloxacin can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Grepafloxacin can be decreased when it is combined with Cholic Acid.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Grepafloxacin.Approved, Investigational
CilazaprilThe serum concentration of Grepafloxacin can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Grepafloxacin can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Grepafloxacin.Approved
CitalopramThe serum concentration of Grepafloxacin can be increased when it is combined with Citalopram.Approved
ClarithromycinThe metabolism of Grepafloxacin can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Grepafloxacin can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Grepafloxacin.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Grepafloxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Grepafloxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Grepafloxacin.Approved
ClofazimineThe serum concentration of Grepafloxacin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Grepafloxacin.Approved, Investigational
ClomipramineThe serum concentration of Grepafloxacin can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Grepafloxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Grepafloxacin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Grepafloxacin.Approved, Nutraceutical
ClotrimazoleThe metabolism of Grepafloxacin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Grepafloxacin.Approved
CobicistatThe metabolism of Grepafloxacin can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Grepafloxacin.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Grepafloxacin.Approved
ColforsinThe serum concentration of Grepafloxacin can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Grepafloxacin can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Grepafloxacin.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Grepafloxacin.Approved
CrizotinibThe metabolism of Grepafloxacin can be decreased when combined with Crizotinib.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Grepafloxacin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Grepafloxacin.Approved, Investigational
CyclosporineThe metabolism of Grepafloxacin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Grepafloxacin can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneD-Limonene may increase the neuroexcitatory activities of Grepafloxacin.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Grepafloxacin.Approved
DabrafenibThe serum concentration of Grepafloxacin can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Grepafloxacin can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Grepafloxacin can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Grepafloxacin.Approved
DarunavirThe metabolism of Grepafloxacin can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Grepafloxacin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Grepafloxacin can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Grepafloxacin.Approved
DeferasiroxThe serum concentration of Grepafloxacin can be decreased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Grepafloxacin.Investigational
DelavirdineThe metabolism of Grepafloxacin can be decreased when combined with Delavirdine.Approved
DesipramineThe serum concentration of Grepafloxacin can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Grepafloxacin.Approved
DesloratadineThe serum concentration of Grepafloxacin can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Grepafloxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Grepafloxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Grepafloxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Grepafloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Grepafloxacin.Vet Approved
DextromethorphanThe serum concentration of Grepafloxacin can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Grepafloxacin.Approved, Illicit, Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Grepafloxacin.Approved, Vet Approved
DicoumarolGrepafloxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Grepafloxacin.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Grepafloxacin.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Grepafloxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Grepafloxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Grepafloxacin.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Grepafloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Grepafloxacin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Grepafloxacin.Approved
DihydroergotamineThe metabolism of Grepafloxacin can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Grepafloxacin.Illicit
DiltiazemThe metabolism of Grepafloxacin can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Grepafloxacin can be increased when it is combined with Dipyridamole.Approved
DisopyramideGrepafloxacin may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Grepafloxacin.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Grepafloxacin.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Grepafloxacin can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Grepafloxacin can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Grepafloxacin.Approved, Investigational
DoxorubicinThe serum concentration of Grepafloxacin can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Grepafloxacin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Grepafloxacin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Grepafloxacin can be decreased when combined with Dronedarone.Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Grepafloxacin.Approved
DulaglutideGrepafloxacin may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the neuroexcitatory activities of Grepafloxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Grepafloxacin.Approved
E6201E6201 may increase the neuroexcitatory activities of Grepafloxacin.Investigational
EbselenEbselen may increase the neuroexcitatory activities of Grepafloxacin.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Grepafloxacin.Approved
EfavirenzThe serum concentration of Grepafloxacin can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Grepafloxacin can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Grepafloxacin.Approved, Investigational
EmpagliflozinGrepafloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe serum concentration of Grepafloxacin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Grepafloxacin can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Grepafloxacin.Approved, Investigational
EpirizoleEpirizole may increase the neuroexcitatory activities of Grepafloxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Grepafloxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Grepafloxacin.Approved
ErgonovineThe serum concentration of Grepafloxacin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Grepafloxacin can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Grepafloxacin.Approved, Investigational
ErythromycinThe metabolism of Grepafloxacin can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Grepafloxacin can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Grepafloxacin.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Grepafloxacin can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Grepafloxacin can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Grepafloxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Grepafloxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Grepafloxacin.Approved
Ethyl biscoumacetateGrepafloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Grepafloxacin.Approved
EtoposideThe serum concentration of Grepafloxacin can be increased when it is combined with Etoposide.Approved
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational
EtravirineThe serum concentration of Grepafloxacin can be decreased when it is combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Grepafloxacin.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Grepafloxacin.Approved
ExenatideGrepafloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the neuroexcitatory activities of Grepafloxacin.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Grepafloxacin.Approved
FelodipineThe serum concentration of Grepafloxacin can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may increase the neuroexcitatory activities of Grepafloxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Grepafloxacin.Approved
FentanylThe serum concentration of Grepafloxacin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferric CarboxymaltoseThe serum concentration of Grepafloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Grepafloxacin can be decreased when it is combined with Ferric Citrate.Approved
Ferric pyrophosphateThe serum concentration of Grepafloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Grepafloxacin.Approved
FexofenadineThe serum concentration of Grepafloxacin can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Grepafloxacin.Approved
FloctafenineFloctafenine may increase the neuroexcitatory activities of Grepafloxacin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Grepafloxacin.Investigational
FluconazoleThe metabolism of Grepafloxacin can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Grepafloxacin.Approved
FluindioneGrepafloxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Grepafloxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Grepafloxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Grepafloxacin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Grepafloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Grepafloxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Grepafloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Grepafloxacin.Approved
FluoxetineThe serum concentration of Grepafloxacin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Grepafloxacin can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Grepafloxacin can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Grepafloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Grepafloxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Grepafloxacin.Approved
FlurazepamThe serum concentration of Grepafloxacin can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Grepafloxacin.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Grepafloxacin.Approved
FluvoxamineThe metabolism of Grepafloxacin can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Grepafloxacin.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Grepafloxacin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Grepafloxacin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Grepafloxacin can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Grepafloxacin can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Grepafloxacin can be increased when it is combined with Gefitinib.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Grepafloxacin.Approved
GenisteinThe serum concentration of Grepafloxacin can be increased when it is combined with Genistein.Investigational
GliclazideGrepafloxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideGrepafloxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideGrepafloxacin may increase the hypoglycemic activities of Glipizide.Approved
GlyburideThe serum concentration of Grepafloxacin can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Grepafloxacin can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Grepafloxacin can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Grepafloxacin.Approved
HaloperidolThe serum concentration of Grepafloxacin can be increased when it is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Grepafloxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Grepafloxacin.Investigational
HMPL-004HMPL-004 may increase the neuroexcitatory activities of Grepafloxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Grepafloxacin.Approved, Vet Approved
IbuprofenIbuprofen may increase the neuroexcitatory activities of Grepafloxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Grepafloxacin.Approved
IdelalisibThe serum concentration of Grepafloxacin can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Grepafloxacin can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Grepafloxacin can be increased when it is combined with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Grepafloxacin.Approved
IndinavirThe metabolism of Grepafloxacin can be decreased when combined with Indinavir.Approved
IndomethacinIndomethacin may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
Insulin AspartGrepafloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirGrepafloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineGrepafloxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineGrepafloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanGrepafloxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproGrepafloxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Grepafloxacin.Approved, Investigational
IronThe serum concentration of Grepafloxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Grepafloxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Grepafloxacin can be decreased when it is combined with Iron saccharate.Approved
IsavuconazoniumThe metabolism of Grepafloxacin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoxicamIsoxicam may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
IsradipineThe metabolism of Grepafloxacin can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Grepafloxacin.Investigational
ItraconazoleThe metabolism of Grepafloxacin can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Grepafloxacin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Grepafloxacin can be increased when it is combined with Ivermectin.Approved, Vet Approved
KebuzoneKebuzone may increase the neuroexcitatory activities of Grepafloxacin.Experimental
KetamineThe serum concentration of Grepafloxacin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Grepafloxacin.Approved
KetoconazoleThe metabolism of Grepafloxacin can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the neuroexcitatory activities of Grepafloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Grepafloxacin.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Grepafloxacin.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Grepafloxacin.Approved, Investigational
LanreotideGrepafloxacin may increase the hypoglycemic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Grepafloxacin can be increased when it is combined with Lansoprazole.Approved, Investigational
Lanthanum carbonateThe serum concentration of Grepafloxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LapatinibThe serum concentration of Grepafloxacin can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Grepafloxacin.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Grepafloxacin.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Grepafloxacin.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Grepafloxacin.Approved, Investigational
LevofloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Grepafloxacin.Approved
LevothyroxineThe serum concentration of Grepafloxacin can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Grepafloxacin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Grepafloxacin.Approved
LiothyronineThe serum concentration of Grepafloxacin can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Grepafloxacin can be decreased when it is combined with Liotrix.Approved
LiraglutideGrepafloxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe serum concentration of Grepafloxacin can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the neuroexcitatory activities of Grepafloxacin.Investigational
LomitapideThe serum concentration of Grepafloxacin can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Grepafloxacin can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Grepafloxacin can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Grepafloxacin can be increased when it is combined with Loratadine.Approved
LornoxicamLornoxicam may increase the neuroexcitatory activities of Grepafloxacin.Approved
LosartanThe serum concentration of Grepafloxacin can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Grepafloxacin can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Grepafloxacin.Approved
LuliconazoleThe serum concentration of Grepafloxacin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Grepafloxacin can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium salicylateThe serum concentration of Grepafloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateThe serum concentration of Grepafloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Grepafloxacin.Approved, Investigational
MaprotilineThe serum concentration of Grepafloxacin can be increased when it is combined with Maprotiline.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Grepafloxacin.Approved
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Grepafloxacin.Investigational
MebendazoleThe serum concentration of Grepafloxacin can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecaserminGrepafloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Grepafloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Grepafloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Grepafloxacin.Approved
MefloquineThe serum concentration of Grepafloxacin can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Grepafloxacin can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Grepafloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Grepafloxacin.Approved, Vet Approved
MeprobamateThe serum concentration of Grepafloxacin can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMesalazine may increase the neuroexcitatory activities of Grepafloxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
MetforminGrepafloxacin may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe serum concentration of Grepafloxacin can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Grepafloxacin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Grepafloxacin.Approved, Vet Approved
MetoprololThe serum concentration of Grepafloxacin can be increased when it is combined with Metoprolol.Approved, Investigational
MexiletineThe metabolism of Grepafloxacin can be decreased when combined with Mexiletine.Approved
MibefradilThe serum concentration of Grepafloxacin can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Grepafloxacin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Grepafloxacin can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Grepafloxacin can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolGrepafloxacin may increase the hypoglycemic activities of Miglitol.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Grepafloxacin.Approved
MitomycinThe serum concentration of Grepafloxacin can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Grepafloxacin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Grepafloxacin can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineMizoribine may increase the neuroexcitatory activities of Grepafloxacin.Investigational
ModafinilThe serum concentration of Grepafloxacin can be decreased when it is combined with Modafinil.Approved, Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Grepafloxacin.Approved, Vet Approved
MorphineThe serum concentration of Grepafloxacin can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Grepafloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Grepafloxacin.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Grepafloxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Grepafloxacin.Investigational
NafcillinThe serum concentration of Grepafloxacin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may increase the neuroexcitatory activities of Grepafloxacin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Grepafloxacin.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Grepafloxacin.Approved, Vet Approved
NaltrexoneThe serum concentration of Grepafloxacin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Grepafloxacin.Approved, Vet Approved
NaringeninThe serum concentration of Grepafloxacin can be increased when it is combined with Naringenin.Experimental
NateglinideGrepafloxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Grepafloxacin.Investigational
NCX 4016NCX 4016 may increase the neuroexcitatory activities of Grepafloxacin.Investigational
NefazodoneThe metabolism of Grepafloxacin can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Grepafloxacin can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Grepafloxacin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacNepafenac may increase the neuroexcitatory activities of Grepafloxacin.Approved
NetupitantThe serum concentration of Grepafloxacin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Grepafloxacin can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Grepafloxacin can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Grepafloxacin can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Grepafloxacin.Approved
NilotinibThe metabolism of Grepafloxacin can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the neuroexcitatory activities of Grepafloxacin.Approved, Withdrawn
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Grepafloxacin.Approved
NisoldipineThe serum concentration of Grepafloxacin can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Grepafloxacin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Grepafloxacin can be increased when it is combined with Nitrendipine.Approved
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Grepafloxacin.Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Grepafloxacin.Approved
NorethisteroneThe serum concentration of Grepafloxacin can be decreased when it is combined with Norethisterone.Approved
OctreotideGrepafloxacin may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Grepafloxacin.Approved, Investigational
OlaparibThe metabolism of Grepafloxacin can be decreased when combined with Olaparib.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Grepafloxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Grepafloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Grepafloxacin.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Grepafloxacin.Approved
OmeprazoleThe serum concentration of Grepafloxacin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Grepafloxacin.Vet Approved
OsimertinibThe serum concentration of Grepafloxacin can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Grepafloxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Grepafloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
P-NitrophenolThe serum concentration of Grepafloxacin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Grepafloxacin.Approved, Vet Approved
PalbociclibThe serum concentration of Grepafloxacin can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Grepafloxacin can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Grepafloxacin.Approved, Investigational
PantoprazoleThe serum concentration of Grepafloxacin can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Grepafloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Grepafloxacin.Approved
ParoxetineThe serum concentration of Grepafloxacin can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideGrepafloxacin may increase the hypoglycemic activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Grepafloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Grepafloxacin can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidineGrepafloxacin may increase the hypoglycemic activities of Pentamidine.Approved
PentobarbitalThe metabolism of Grepafloxacin can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Grepafloxacin can be increased when it is combined with Perindopril.Approved
PhenindioneGrepafloxacin may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Grepafloxacin can be increased when combined with Phenobarbital.Approved
PhenprocoumonGrepafloxacin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Grepafloxacin.Approved, Vet Approved
PhenytoinThe metabolism of Grepafloxacin can be increased when combined with Phenytoin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Grepafloxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational
PimozideThe serum concentration of Grepafloxacin can be increased when it is combined with Pimozide.Approved
PioglitazoneGrepafloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Grepafloxacin.Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Grepafloxacin.Approved
Platelet Activating FactorThe serum concentration of Grepafloxacin can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Grepafloxacin.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Grepafloxacin.Approved
PosaconazoleThe metabolism of Grepafloxacin can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideGrepafloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Grepafloxacin.Approved, Nutraceutical
PravastatinThe serum concentration of Grepafloxacin can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Grepafloxacin can be increased when it is combined with Prazosin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Grepafloxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Grepafloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Grepafloxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Grepafloxacin.Experimental
PrimidoneThe metabolism of Grepafloxacin can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Grepafloxacin can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Grepafloxacin can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Grepafloxacin can be increased when it is combined with Promethazine.Approved
PropacetamolPropacetamol may increase the neuroexcitatory activities of Grepafloxacin.Approved
PropafenoneThe serum concentration of Grepafloxacin can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Grepafloxacin can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Grepafloxacin can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Grepafloxacin.Approved
PTC299PTC299 may increase the neuroexcitatory activities of Grepafloxacin.Investigational
QuercetinThe serum concentration of Grepafloxacin can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Grepafloxacin.Approved
QuinacrineThe serum concentration of Grepafloxacin can be increased when it is combined with Quinacrine.Approved
QuinaprilThe serum concentration of Grepafloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Grepafloxacin can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Grepafloxacin can be increased when it is combined with Quinine.Approved
RanitidineThe serum concentration of Grepafloxacin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Grepafloxacin.Approved, Investigational
ReboxetineThe serum concentration of Grepafloxacin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Grepafloxacin can be increased when it is combined with Regorafenib.Approved
RepaglinideGrepafloxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReserpineThe serum concentration of Grepafloxacin can be decreased when it is combined with Reserpine.Approved
ResveratrolResveratrol may increase the neuroexcitatory activities of Grepafloxacin.Experimental, Investigational
RifabutinThe metabolism of Grepafloxacin can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Grepafloxacin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Grepafloxacin can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Grepafloxacin.Approved, Investigational
RilpivirineThe serum concentration of Grepafloxacin can be increased when it is combined with Rilpivirine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Grepafloxacin.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Grepafloxacin.Approved, Investigational
RitonavirThe metabolism of Grepafloxacin can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Grepafloxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
RolapitantThe serum concentration of Grepafloxacin can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Grepafloxacin.Approved, Investigational
RopiniroleThe metabolism of Grepafloxacin can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneGrepafloxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalicylamideSalicylamide may increase the neuroexcitatory activities of Grepafloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Grepafloxacin.Approved, Vet Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Grepafloxacin.Approved
SaquinavirThe metabolism of Grepafloxacin can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinGrepafloxacin may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe serum concentration of Grepafloxacin can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Grepafloxacin can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Grepafloxacin.Approved
SeratrodastSeratrodast may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational
SertralineThe serum concentration of Grepafloxacin can be increased when it is combined with Sertraline.Approved
SevelamerSevelamer can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SildenafilThe metabolism of Grepafloxacin can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Grepafloxacin.Approved
SiltuximabThe serum concentration of Grepafloxacin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Grepafloxacin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Grepafloxacin can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Grepafloxacin can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Grepafloxacin.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Grepafloxacin.Approved
SorafenibThe serum concentration of Grepafloxacin can be increased when it is combined with Sorafenib.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Grepafloxacin.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Grepafloxacin.Experimental
SpironolactoneThe serum concentration of Grepafloxacin can be increased when it is combined with Spironolactone.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Grepafloxacin.Investigational
St. John's WortThe serum concentration of Grepafloxacin can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Grepafloxacin can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Grepafloxacin can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Grepafloxacin can be decreased when it is combined with Streptozocin.Approved
Strontium ranelateThe serum concentration of Grepafloxacin can be decreased when it is combined with Strontium ranelate.Approved
SucralfateThe serum concentration of Grepafloxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineGrepafloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleGrepafloxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Grepafloxacin.Approved
SulfinpyrazoneThe serum concentration of Grepafloxacin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Grepafloxacin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Grepafloxacin.Approved
SumatriptanThe serum concentration of Grepafloxacin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Grepafloxacin can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Grepafloxacin.Approved, Withdrawn
TacrineThe serum concentration of Grepafloxacin can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Grepafloxacin can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Grepafloxacin can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Grepafloxacin can be increased when it is combined with Taurocholic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Grepafloxacin.Approved
TelaprevirThe metabolism of Grepafloxacin can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Grepafloxacin can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Grepafloxacin can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Grepafloxacin.Approved
TenofovirThe metabolism of Grepafloxacin can be decreased when combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may increase the neuroexcitatory activities of Grepafloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Grepafloxacin.Vet Approved
TerazosinThe serum concentration of Grepafloxacin can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Grepafloxacin can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Grepafloxacin can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Grepafloxacin can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Grepafloxacin can be increased when it is combined with Testosterone.Approved, Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Grepafloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Grepafloxacin.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Grepafloxacin.Approved
TiclopidineThe metabolism of Grepafloxacin can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Grepafloxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Grepafloxacin.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Grepafloxacin.Approved
TocilizumabThe serum concentration of Grepafloxacin can be decreased when it is combined with Tocilizumab.Approved
TolazamideGrepafloxacin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideGrepafloxacin may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Grepafloxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Grepafloxacin.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Grepafloxacin.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Grepafloxacin.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Grepafloxacin.Approved, Investigational
TranilastTranilast may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Grepafloxacin.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Grepafloxacin.Approved
TrazodoneThe serum concentration of Grepafloxacin can be decreased when it is combined with Trazodone.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Grepafloxacin.Approved, Vet Approved
TrifluoperazineThe serum concentration of Grepafloxacin can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Grepafloxacin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Grepafloxacin can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Grepafloxacin can be increased when it is combined with Trimipramine.Approved
Trisalicylate-cholineTrisalicylate-choline may increase the neuroexcitatory activities of Grepafloxacin.Approved
TroleandomycinThe serum concentration of Grepafloxacin can be increased when it is combined with Troleandomycin.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Grepafloxacin.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Grepafloxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Grepafloxacin.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Grepafloxacin.Approved
VemurafenibThe serum concentration of Grepafloxacin can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Grepafloxacin.Approved
VenlafaxineThe metabolism of Grepafloxacin can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Grepafloxacin can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Grepafloxacin can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Grepafloxacin.Approved, Investigational
VincristineThe serum concentration of Grepafloxacin can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Grepafloxacin can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Grepafloxacin.Approved
VoriconazoleThe metabolism of Grepafloxacin can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinGrepafloxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Grepafloxacin.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Grepafloxacin.Approved
ZileutonZileuton may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Grepafloxacin can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Grepafloxacin can be decreased when combined with Ziprasidone.Approved
ZomepiracZomepirac may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
Food Interactions
  • Drink liberally but avoid coffee.
  • Take without regard to meals.
References
Synthesis Reference

DrugSyn.org

US4920120
General ReferencesNot Available
External Links
ATC CodesJ01MA11
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (115 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9886
Blood Brain Barrier-0.9855
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.8825
P-glycoprotein inhibitor INon-inhibitor0.9062
P-glycoprotein inhibitor IINon-inhibitor0.9228
Renal organic cation transporterNon-inhibitor0.7877
CYP450 2C9 substrateNon-substrate0.8299
CYP450 2D6 substrateNon-substrate0.9127
CYP450 3A4 substrateNon-substrate0.7079
CYP450 1A2 substrateNon-inhibitor0.8516
CYP450 2C9 inhibitorNon-inhibitor0.9197
CYP450 2D6 inhibitorNon-inhibitor0.9365
CYP450 2C19 inhibitorNon-inhibitor0.9064
CYP450 3A4 inhibitorNon-inhibitor0.8116
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.763
Ames testAMES toxic0.7309
CarcinogenicityNon-carcinogens0.8042
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.0923 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9009
hERG inhibition (predictor II)Non-inhibitor0.7785
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Otsuka pharmaceutical co ltd
Packagers
Dosage forms
FormRouteStrength
TabletOral200 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1340492 No1999-04-132016-04-13Canada
US5563138 No1993-10-082013-10-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.632 mg/mLALOGPS
logP-0.12ALOGPS
logP0.12ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)5.88ChemAxon
pKa (Strongest Basic)8.77ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area72.88 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity97.4 m3·mol-1ChemAxon
Polarizability37.69 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassQuinoline carboxylic acids
Direct ParentQuinoline carboxylic acids
Alternative Parents
Substituents
  • Quinoline-3-carboxylic acid
  • N-arylpiperazine
  • Fluoroquinolone
  • Dihydroquinolone
  • Aminoquinoline
  • Dihydroquinoline
  • Pyridine carboxylic acid or derivatives
  • Pyridine carboxylic acid
  • Dialkylarylamine
  • Fluorobenzene
  • Benzenoid
  • Pyridine
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Vinylogous amide
  • Tertiary amine
  • Azacycle
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Secondary aliphatic amine
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.
Gene Name:
gyrA
Uniprot ID:
P43700
Molecular Weight:
97817.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Stewart BA, Johnson AP, Woodford N: Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin. J Med Microbiol. 1999 Dec;48(12):1103-6. [PubMed:10591164 ]
  4. Jorgensen JH, Weigel LM, Ferraro MJ, Swenson JM, Tenover FC: Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob Agents Chemother. 1999 Feb;43(2):329-34. [PubMed:9925527 ]
  5. Griggs DJ, Marona H, Piddock LJ: Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones. J Antimicrob Chemother. 2003 Jun;51(6):1403-7. Epub 2003 Apr 25. [PubMed:12716775 ]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name:
parC
Uniprot ID:
P43702
Molecular Weight:
83366.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Ernst EJ, Klepser ME, Petzold CR, Doern GV: Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection. Pharmacotherapy. 2002 Apr;22(4):463-70. [PubMed:11939681 ]
  4. Morris JE, Pan XS, Fisher LM: Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in target specificity. Antimicrob Agents Chemother. 2002 Feb;46(2):582-5. [PubMed:11796384 ]
  5. Kawamura-Sato K, Hasegawa T, Torii K, Ito H, Ohta M: Prevalence of Ile-460-Val/ParE substitution in clinical Streptococcus pneumoniae isolates that were less susceptible to fluoroquinolones. Curr Microbiol. 2005 Jul;51(1):27-30. Epub 2005 May 31. [PubMed:15942701 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Rodighiero V: Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet. 1999 Nov;37(5):399-431. [PubMed:10589374 ]
  2. Bril F, Gonzalez CD, Di Girolamo G: Antimicrobial agents-associated with QT interval prolongation. Curr Drug Saf. 2010 Jan;5(1):85-92. [PubMed:20210724 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Pal D, Mitra AK: MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol. 2006 Sep;1(3):323-39. Epub 2006 Aug 2. [PubMed:18040809 ]
  2. Owens RC Jr: QT prolongation with antimicrobial agents: understanding the significance. Drugs. 2004;64(10):1091-124. [PubMed:15139788 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Yamaguchi H, Yano I, Hashimoto Y, Inui KI: Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2. J Pharmacol Exp Ther. 2000 Oct;295(1):360-6. [PubMed:10992002 ]
  2. Naruhashi K, Tamai I, Inoue N, Muraoka H, Sai Y, Suzuki N, Tsuji A: Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein. J Pharm Pharmacol. 2001 May;53(5):699-709. [PubMed:11370709 ]
  3. Yamaguchi H, Yano I, Saito H, Inui K: Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharm Res. 2004 Feb;21(2):330-8. [PubMed:15032316 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Tamai I, Yamashita J, Kido Y, Ohnari A, Sai Y, Shima Y, Naruhashi K, Koizumi S, Tsuji A: Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J Pharmacol Exp Ther. 2000 Oct;295(1):146-52. [PubMed:10991972 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Uwai Y, Okuda M, Takami K, Hashimoto Y, Inui K: Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett. 1998 Nov 6;438(3):321-4. [PubMed:9827570 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10. [PubMed:12089365 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Sasabe H, Tsuji A, Sugiyama Y: Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. J Pharmacol Exp Ther. 1998 Mar;284(3):1033-9. [PubMed:9495864 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23